{"filing":{"accession_number":"0001140361-26-025207","cik":"0001472091","ticker":"PDSB","company_name":"PDS Biotechnology Corp","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"ef20076071_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126025207/ef20076071_8k.htm"},"events":[{"id":10983,"run_id":9628,"accession_number":"0001140361-26-025207","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"PDS Biotechnology closed a Securities Purchase Agreement with YA II PN, LTD. on June 15, 2026, issuing a $6,000,000 promissory note convertible into common stock and a warrant to purchase 2,158,274 shares at $1.1824/share, plus establishing a $50,000,000 at-the-market offering program. This private placement under Section 4(a)(2) and Regulation D Rule 506 materially dilutes shareholder equity and voting power.","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7448,"accession_number":"0001140361-26-025207","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"PDS Biotechnology closed a Securities Purchase Agreement with YA II PN, LTD. on June 15, 2026, issuing a $6,000,000 promissory note and a warrant to purchase 2,158,274 shares at $1.1824/share, plus establishing a $50,000,000 at-the-market offering program. This is a classic dilutive financing structure combining debt with equity warrants and an ATM offering, materially affecting shareholder equity and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:02:16.401553+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7451,"accession_number":"0001140361-26-025207","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities comprising a Promissory Note convertible into Common Stock and a Warrant exercisable for Common Stock, issued to an accredited investor under Section 4(a)(2) and Regulation D Rule 506. This is a classic private placement with dilutive equity components that would materially affect shareholder ownership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:02:16.401553+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10984,"run_id":9628,"accession_number":"0001140361-26-025207","anchor_item_number":"1.02","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"PDS Biotechnology redeemed and fully prepaid all outstanding Senior Secured Convertible Debentures issued under a Securities Purchase Agreement dated April 30, 2025, paying 103% of principal plus accrued interest. This debt retirement and capital restructuring materially affects the company's financial obligations and capital structure.","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7449,"accession_number":"0001140361-26-025207","item_number":"1.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The filing discloses termination of a material definitive agreement—specifically the redemption and full prepayment of Senior Secured Convertible Debentures issued under a Securities Purchase Agreement dated April 30, 2025. While Item 1.02 is technically \"Termination of a Material Definitive Agreement,\" the substance here is debt retirement and capital restructuring. The company paid 103% of principal plus accrued interest to redeem all outstanding debentures, which is a material financing event affecting the company's capital structure and debt obligations. This is classified as ma_activity because it represents a material change in the company's financial obligations and capital structure, though it could also fit other_material if viewed purely as agreement termination.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:02:16.401553+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7450,"accession_number":"0001140361-26-025207","item_number":"2.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Item 2.03 discloses creation of a direct financial obligation, with the substance incorporated by reference from Items 1.01 and 1.02. Item 1.01 typically covers material acquisitions or dispositions, and Item 1.02 covers termination of material agreements. The redemption and termination of Debentures signals a material restructuring of the company's debt obligations, which constitutes a material financial event affecting the registrant's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:02:16.401553+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7452,"accession_number":"0001140361-26-025207","item_number":"3.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The disclosure describes redemption of Debentures on a Closing Date, which extinguished the rights of debenture holders including conversion rights into Common Stock. This constitutes a material modification of security holder rights through a debt redemption/retirement event, typically associated with M\u0026A activity or significant capital restructuring. The reference to Item 1.02 (which covers acquisitions/dispositions) suggests this redemption is part of a broader transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:02:16.401553+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7448,"accession_number":"0001140361-26-025207","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"PDS Biotechnology closed a Securities Purchase Agreement with YA II PN, LTD. on June 15, 2026, issuing a $6,000,000 promissory note and a warrant to purchase 2,158,274 shares at $1.1824/share, plus establishing a $50,000,000 at-the-market offering program. This is a classic dilutive financing structure combining debt with equity warrants and an ATM offering, materially affecting shareholder equity and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:02:16.401553+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-06-15"},{"id":7449,"accession_number":"0001140361-26-025207","item_number":"1.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The filing discloses termination of a material definitive agreement—specifically the redemption and full prepayment of Senior Secured Convertible Debentures issued under a Securities Purchase Agreement dated April 30, 2025. While Item 1.02 is technically \"Termination of a Material Definitive Agreement,\" the substance here is debt retirement and capital restructuring. The company paid 103% of principal plus accrued interest to redeem all outstanding debentures, which is a material financing event affecting the company's capital structure and debt obligations. This is classified as ma_activity because it represents a material change in the company's financial obligations and capital structure, though it could also fit other_material if viewed purely as agreement termination.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:02:16.401553+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-06-15"},{"id":7450,"accession_number":"0001140361-26-025207","item_number":"2.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Item 2.03 discloses creation of a direct financial obligation, with the substance incorporated by reference from Items 1.01 and 1.02. Item 1.01 typically covers material acquisitions or dispositions, and Item 1.02 covers termination of material agreements. The redemption and termination of Debentures signals a material restructuring of the company's debt obligations, which constitutes a material financial event affecting the registrant's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:02:16.401553+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-06-15"},{"id":7451,"accession_number":"0001140361-26-025207","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities comprising a Promissory Note convertible into Common Stock and a Warrant exercisable for Common Stock, issued to an accredited investor under Section 4(a)(2) and Regulation D Rule 506. This is a classic private placement with dilutive equity components that would materially affect shareholder ownership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:02:16.401553+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-06-15"},{"id":7452,"accession_number":"0001140361-26-025207","item_number":"3.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The disclosure describes redemption of Debentures on a Closing Date, which extinguished the rights of debenture holders including conversion rights into Common Stock. This constitutes a material modification of security holder rights through a debt redemption/retirement event, typically associated with M\u0026A activity or significant capital restructuring. The reference to Item 1.02 (which covers acquisitions/dispositions) suggests this redemption is part of a broader transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:02:16.401553+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-06-15"}]}